**Shingrix® Immunization for Patients Before and After Solid Organ Transplantation**

The shingles vaccine, Shingrix® (recombinant vaccine), is used to protect against shingles and postherpetic neuralgia. Shingrix® is more than 90% effective in preventing shingles, and there is no live virus in the vaccine. The Advisory Committee on Immunization Practices (ACIP) currently recommends all healthy, immunocompetent adults age 50 years and older, and all patients 19 years and older who are immunocompromised, receive the Shingrix® vaccine.

The Emory Transplant Center is recommending all patients age 19 years and older who have received a transplant or are listed for a transplant should receive 2 doses of the Shingrix® vaccine separated by 2-6 months.

* Patients can still receive Shingrix® if they had shingles in the past, have received Zostavax® already, or are not sure if they had chickenpox.
* Patients should **NOT** receive Shingrix® if:
	+ they have had a severe reaction to any component of the vaccine
	+ currently have shingles
	+ currently pregnant or breastfeeding
* Patients who have had Shingles disease should receive the Shingrix® vaccine series if they otherwise qualify. However, these patients should wait at least 6 months after resolution of the disease prior to receiving the Shingrix® vaccine
* Patients should **not** receiveShingrix® and Heplisav-B® or Fluad® on the same day. Patients should wait 4 weeks after receiving Heplisav-B® or Fluad® before receiving Shingrix®.
* It is safe to administer other vaccines on the same day as Shingrix®, but it is advised to use two different anatomical sites.
* The side effects of the Shingrix are temporary and usually last 2 to 3 days. While you may experience pain for a few days after getting Shingrix, the pain will be less severe than having shingles and the complications from the disease.

Pre-Transplant Patients:

* Shingrix® is recommended for patients age 19 years or older who are being listed for a solid organ transplant.

Post-Transplant Patients:

* All patients aged 19 years and older who are ≥ 6 months post-transplant are encouraged to receive the Shingrix® vaccine.
* All patients treated for rejection should wait until 3 months after treatment to receive the Shingrix® vaccine series.

**REFERENCES AND SOURCES OF EVIDENCE:**

www.cdc.gov/vaccines/vpd/shingles/public/shingrix/